Gilead Signs PAHO Deal to Broaden Lenacapavir HIV Prevention Access Across Latin America

Gilead Sciences (Nasdaq: GILD) this week announced a pivotal new agreement with the Pan American Health Organization (PAHO) to expand access to its long‑acting HIV prevention therapy, lenacapavir, across Latin America and the Caribbean.

New Regional Procurement Pathway via PAHO

On September 15, 2026, Gilead and PAHO unveiled a coordinated agreement enabling 14 countries—including Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay, and Venezuela—to access twice‑yearly injectable lenacapavir through PAHO’s Regional Revolving Funds, subject to national approvals and program implementation plans. This regional access mechanism complements existing voluntary licensing pathways and strengthens Gilead’s global PrEP access strategy. According to the Pan American Health Organization, this agreement marks a significant step toward improving HIV prevention coverage in the region.  

The framework builds on Gilead’s broader approach combining voluntary licensing, technology transfer, no‑profit supply, and regional procurement partnerships. While voluntary licensing covers generic production in 120 countries (including parts of Latin America and the Caribbean), these 14 nations fall outside that remit. The new PAHO channel addresses those gaps and aims to accelerate implementation.  

Manufacturing and Strategic Commitments

Gilead has also committed to initiating a technology‑transfer process in Brazil aimed at enabling future local production of lenacapavir, though specific timelines remain undefined. This represents a forward-looking move toward building sustainable regional supply capabilities.

Earlier, Gilead had expanded voluntary licensing agreements to include investigational once‑yearly lenacapavir, nurturing manufacturing preparedness and healthcare systems ahead of Phase 3 trial results. The company also recently increased its no‑profit supply commitment through PEPFAR and the Global Fund to reach up to 3 million people through 2028. 

Why It Matters for Gilead Investors

This development may indirectly bolster investor confidence in Gilead’s HIV prevention franchise by extending lenacapavir’s reach into previously underserved markets. However, it’s important to note that this is an access and policy-level deal—not a revenue-driving market launch. The financial implications will depend on country uptake, regulatory approvals, pricing models, and supply execution.

Closing Outlook

The PAHO agreement underlines Gilead’s commitment to global health and is poised to enhance access to twice‑yearly HIV prevention in Latin America and the Caribbean. Investors should monitor the progress of country-level regulatory adoption, the initiation of local manufacturing in Brazil, and how the broader rollout through PAHO influences demand and cost dynamics.

Stock snapshot: Gilead’s shares last closed at $149.69, down 0.93% on September 24, 2026. While this agreement may not immediately impact earnings, it reinforces the company’s long-term access strategy—and may bear strategic weight as lenacapavir transitions from clinical innovation to widespread implementation.